匹配供者同种异体CAR-T治疗成人B细胞急性淋巴细胞白血病:毒性、疗效、重复给药及淋巴细胞清除的重要性
本研究开发了匹配供者同种异体CD19 CAR产品(CAR-DLI),用于异基因造血干细胞移植后失败的成人B-ALL患者。14例患者接受输注,其中7例单用CAR-DLI,7例联合淋巴细胞清除化疗(氟达拉滨/环磷酰胺)。联合淋巴细胞清除组在植入峰值、扩增和持久性上均优于单用组,且未增加免疫毒性,12个月无事件生存率和总生存率更优;重复CAR-DLI给药未显示有效性。
要点
- CAR-DLI联合淋巴细胞清除化疗较单用CAR-DLI显著提高植入峰值(93134 vs 8010 copies/μg gDNA)。
- 联合组12个月无事件生存率和总生存率均优于单用组(57% vs 29%;83% vs 29%)。
- 重复CAR-DLI给药未显示有效性,且植入/扩增及毒性/疗效均极小。
核心结论
- CAR-DLI联合淋巴细胞清除化疗安全性可耐受,无显著GVHD,且结局显著优于单用CAR-DLI。
- 本分析中,超过第1剂后的重复CAR-DLI给药未发现有效。
研究设计与样本
- 研究纳入17例异基因造血干细胞移植供者接受白细胞分离,14例B-ALL患者(中位年龄43岁)接受CAR-DLI输注。
- 患者1至7接受单用CAR-DLI,患者8至14接受CAR-DLI联合氟达拉滨/环磷酰胺淋巴细胞清除化疗。
- 主要结局为毒性和CAR-DLI制备可行性,次要结局包括植入、扩增和持久性。
- 试验注册号NCT02893189。
主要发现
- 入组时中位疾病负荷为骨髓原始细胞50.5%(范围:可测量残留病至100%)。
- CAR-DLI+LD组 vs CAR-DLI单用组的峰值植入为93134 vs 8010 copies/μg gDNA。
- CAR-DLI+LD组 vs CAR-DLI单用组的扩增为858101 vs 39038 copies/μg gDNA每28天。
- CAR-DLI+LD组 vs CAR-DLI单用组的中位持久性为197 vs 32天。
- CAR-DLI+LD组 vs CAR-DLI单用组的12个月无事件生存率为57% vs 29%,总生存率为83% vs 29%。
关键数值与推荐
- CAR-DLI+LD与CAR-DLI单用相比,峰值植入、扩增和持久性均更优。
- CAR-DLI+LD未比CAR-DLI单用增加免疫毒性。
- 8/14例(57%)形态学/可测量残留病阳性复发患者接受重复CAR-DLI给药,但植入/扩增或毒性/疗效均极小。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We developed an allogeneic matched donor CD19 chimeric antigen receptor (CAR) product (CAR-donor lymphocyte infusion [DLI]) for adult patients with B-cell acute lymphoblastic leukemia (B-ALL) after failure of allogeneic stem-cell transplantation (allo-SCT). We evaluate the risks and benefits of pre-CAR-DLI lymphodepleting chemotherapy (LD) and the efficacy of repeat CAR-DLI dosing per conventional DLI protocols. Primary outcomes were toxicity and feasibility of CAR-DLI manufacture; secondary outcomes included CAR-DLI engraftment, expansion, and persistence. A total of 17 allo-SCT donors received leukapheresis and 14 patients with B-ALL (median age, 43 years) received infusion. Median disease burden at registration was 50.5% bone marrow blasts (range, measurable residual disease [MRD] to 100%). Patients 1 to 7 received CAR-DLI alone (CAR-DLI-alone); patients 8 through 14 received CAR-DLI and LD with fludarabine/cyclophosphamide (CAR-DLI+LD). CAR-DLI+LD vs CAR-DLI-alone was associated with superior peak CAR-DLI engraftment (93 134 vs 8010 copies per μg genomic DNA [gDNA]), expansion (858 101 vs 39 038 copies per μg gDNA per 28 days) and persistence (median, 197 vs 32 days). CAR-DLI+LD was not associated with more immunotoxicity than CAR-DLI-alone, and graft-versus-host disease (GVHD; grade 1, skin) affected only 2 of 14 patients (14%). CAR-DLI+LD vs CAR-DLI-alone conferred superior event-free-survival and overall survival at 12 months (57% vs 29%; 83% vs 29%). Repeat CAR-DLI dosing was administered to 8 of 14 (57%) patients with morphological/MRD+ relapse, but with minimal engraftment/expansion or toxicity/efficacy. CAR-DLI+LD has a tolerable safety profile without significant GVHD and is associated with significantly better outcomes than CAR-DLI-alone. Repeat CAR-DLI dosing beyond dose 1 was not found to be effective in this analysis. This trial was registered at www.clinicaltrials.gov as #NCT02893189.
引用
- Roddie C, Dias J, O'Reilly MA, et al. Matched donor allogeneic CAR-T for adult B-ALL: toxicity, efficacy, repeat dosing, and the importance of lymphodepletion. Blood. 2025. PMID: 40643148. doi:10.1182/blood.2025028790
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。